Hematologic Malignancies Articles | Page 2

Combination Therapies Poised to Improve CLL Treatment Landscape
Aaron Logan, MD, PhD, discusses the most promising combinations and available treatments for patients with chronic lymphocytic leukemia.
FDA Approves Denosumab for Multiple Myeloma
The FDA has approved denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.
Interferon Continues to Show Promise as Myelofibrosis Option
Patients with myeloproliferative neoplasm‒associated myelofibrosis had prolonged treatment duration and improved survival compared with historical controls when treated with pegylated interferon alfa-2a.
FDA Grants Frontline Eltrombopag Breakthrough Designation for Severe Aplastic Anemia
The FDA has granted a breakthrough therapy designation to eltrombopag (Promacta) for use in combination with standard immunosuppressive therapy as a first-line treatment for patients with severe aplastic anemia.
Venetoclax Demonstrates Strong Activity in CLL After BCR Inhibitor
Patients with relapsed/refractory CLL who failed on previous treatment with a BCR signaling pathway inhibitor had an overall response rate of 65% following treatment with venetoclax (Venclexta).
Long-Term Ibrutinib Follow-up Demonstrates Continued Efficacy in MCL
More than one-quarter of patients with relapsed/refractory mantle cell lymphoma remained progression free and nearly half were alive at 3 years when treated with the BTK inhibitor ibrutinib (Imbruvica). 
FDA Grants Priority Review to Frontline Brentuximab Vedotin for Hodgkin Lymphoma
The FDA has granted a priority review to a supplemental biologics license application for brentuximab vedotin (Adcetris) in combination with Adriamycin, vinblastine, and dacarbazine (AVD) as a frontline treatment for advanced classical Hodgkin lymphoma.
Combination Checkpoint Therapy Gains Ground in AML and MDS
Rational combinations of immune checkpoint inhibitors with other standard antileukemic agents may be needed to improve the response rates, the durability of response, and the overall survival in patients with AML/MDS.
After several decades without a new therapy, the approval of 4 treatments for acute myeloid leukemia over the span of just 4 months is either a total coincidence or an inevitable occurrence.
A new drug application has been submitted for ivosidenib for patients with relapsed/refractory IDH1-mutant acute myeloid leukemia, according to a statement from Agios Pharmaceuticals, the company developing the targeted therapy.
Publication Bottom Border
Border Publication